Approval spans early and levodopa-treated disease; a 6-week titration and CYP3A interactions put pharmacists at the center of starting therapy.
|Videos|October 14, 2014
Pharmacy Times Asks a Walgreens Pharmacist: What Are Your Wellness Initiatives?
Chirag Patel, PharmD, a Walgreens pharmacist in Union, New Jersey, describes the wellness initiatives that Walgreens pharmacists are introducing to patients.
Advertisement
Chirag Patel, PharmD, a Walgreens pharmacist in Union, New Jersey, describes the wellness initiatives that Walgreens pharmacists are introducing to patients.
“What this program does is it offers them savings, it helps them earn points on anything they purchase in the store, including prescriptions,” he says. “It also rewards them for healthy activities.”
Advertisement
Related to this article
Novo's topline phase 3 data show 12.4% weight loss with CagriSema 1.0 mg/1.0 mg in type 2 diabetes and 21.0% in adults with overweight or obesity.
Researchers found substantial overlap in autonomic symptoms, orthostatic tachycardia, and functional impairment between long COVID and POTS.
A review of 69 studies finds influenza vaccines continue to reduce hospitalization and death, with no new safety concerns.
Isatuximab plus Iberdomide maintenance helps MRD-positive myeloma patients turn MRD-negative after transplant, with manageable safety.
Insulin efsitora alfa-gobe (Onswik; Eli Lilly and Company) is designed to deliver steady basal insulin levels over a full 7-day duration.
Vallerie McLaughlin, MD, explains why the ERS update strongly recommends sotatercept for patients with pulmonary arterial hypertension (PAH) who don't reach low-risk status on initial therapy.
Imaging data from the CONTENTed study suggest the type 2 inflammation that drives severe asthma may affect more than the airways.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Ramantamig's 93.6% ORR and Outpatient CRS Control
2
Nearly Two-Thirds of Patients With Long COVID Meet Diagnostic Criteria for POTS
3
Teclistamab-Daratumumab Intensification Achieves 73% MRD-Negative CR Rate in High-Risk Multiple Myeloma
4
FDA Approves Tavapadon, First D1/D5 Agonist for Parkinson Disease
5